GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Capital Expenditure

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Capital Expenditure : $-1.98 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Parnell Pharmaceuticals Holdings's cash flow for capital expenditures for the six months ended in Dec. 2018 was $-1.98 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2018 was $-1.98 Mil.

Parnell Pharmaceuticals Holdings Capital Expenditure Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Capital Expenditure Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Capital Expenditure
Get a 7-Day Free Trial -1.80 -6.92 -3.73 -1.94 -1.98

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Capital Expenditure Get a 7-Day Free Trial -1.80 -6.92 -3.73 -1.94 -1.98

Parnell Pharmaceuticals Holdings Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2018 was $-1.98 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Capital Expenditure
Comparable Companies
OWCP CXUS CANB CNABQ LITH APPB GSRX PCYN EVIO GENH ZTS TSE:4502 XTER:MRK HKSE:03692 TSE:4523 SZSE:000661 TSE:4507 SZSE:000538 NSE:SUNPHARMA SZSE:300601
Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Website
https://www.parnell.com
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.